Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.45 |
| ▸ | CNR1 | P21554 | 17/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22525342 | 0.89 | FFAR4 (0.40) | CNR2CNR1CYP4F2CYP4A11 | |
| SCHEMBL25122747 | 0.86 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL27018353 | 0.85 | CNR1 (0.47) | CNR2CNR1CYP4F2CYP4A11 | |
| SCHEMBL25123317 | 0.85 | CNR2 (0.45) | CNR2CNR1 | |
| SCHEMBL25123338 | 0.81 | PPARA (0.55) | CNR2CNR1 | |
| SCHEMBL25123363 | 0.77 | FFAR1 (0.44) | CNR2CNR1 | |
| SCHEMBL24029374 | 0.76 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL25122727 | 0.76 | PPARG (0.40) | CYP4F2CYP4A11 | |
| SCHEMBL24847860 | 0.75 | MTNR1A (0.33) | CNR2CNR1CYP4F2CYP4A11 | |
| SCHEMBL29307145 | 0.75 | CNR1 (0.47) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | CNR2 2461/4885CNR1 2602/4885CYP4F2 769/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | CNR2 2940/4885CNR1 2779/4885CYP4F2 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.